- Home
- SLND vs YMAB Comparison
SLND vs YMAB Comparison
Compare SLND & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- YMAB
- Stock Information
- Founded
- SLND 1900
- YMAB 2015
- Country
- SLND United States
- YMAB United States
- Employees
- SLND N/A
- YMAB N/A
- Industry
- SLND Military/Government/Technical
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- YMAB Health Care
- Exchange
- SLND Nasdaq
- YMAB Nasdaq
- Market Cap
- SLND 175.8M
- YMAB 192.4M
- IPO Year
- SLND N/A
- YMAB 2018
- Fundamental
- Price
- SLND $4.49
- YMAB $4.30
- Analyst Decision
- SLND Strong Buy
- YMAB Buy
- Analyst Count
- SLND 1
- YMAB 11
- Target Price
- SLND $5.00
- YMAB $17.55
- AVG Volume (30 Days)
- SLND 72.5K
- YMAB 204.2K
- Earning Date
- SLND 08-11-2025
- YMAB 08-11-2025
- Dividend Yield
- SLND N/A
- YMAB N/A
- EPS Growth
- SLND N/A
- YMAB N/A
- EPS
- SLND N/A
- YMAB N/A
- Revenue
- SLND $931,568,000.00
- YMAB $88,658,000.00
- Revenue This Year
- SLND $3.76
- YMAB N/A
- Revenue Next Year
- SLND $1.08
- YMAB $15.15
- P/E Ratio
- SLND N/A
- YMAB N/A
- Revenue Growth
- SLND N/A
- YMAB 4.92
- 52 Week Low
- SLND $1.85
- YMAB $3.55
- 52 Week High
- SLND $4.67
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- SLND 71.29
- YMAB 42.53
- Support Level
- SLND $3.66
- YMAB $3.90
- Resistance Level
- SLND $4.62
- YMAB $5.33
- Average True Range (ATR)
- SLND 0.26
- YMAB 0.36
- MACD
- SLND 0.05
- YMAB -0.08
- Stochastic Oscillator
- SLND 87.04
- YMAB 27.97
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.